Research Director, Chemist


Penelope Bouziotis (Chemist, PhD in Radiochemistry, Department of Chemistry, National and Kapodistrian University of Athens) is a Research Director at the Institute of Nuclear and Radiological Sciences & Technology, Energy & Safety (INRASTES) of the National Center for Scientific Research “Demokritos”. She has been Head of the Radiochemical Studies Laboratory since 2007, as well as the person responsible for the Animal Housing Facility which is licensed by the Prefecture of Athens (license No. EL 25 BIO 022). She is also head of the Radiopharmaceutical Quality Control Laboratory, which has been operating for many years, providing specialized scientific and technological services to the National Drug Organization and the Nuclear Medicine Departments of the country.

Dr. Bouziotis is involved in the development of diagnostic and therapeutic radiopharmaceuticals for cancer, with an emphasis on the radiolabeling of biomolecules (peptides/peptidomimetics/monoclonal antibodies) with a number of radioisotopes for the diagnosis of primary cancer and metastases with SPECT/PET/CT (with gamma and positron-emitting radioisotopes such as Gallium-68, Technetium-99m, Fluorine-18, Zirconium-89) and their treatment (with alpha- and beta-particle emitting radioisotopes such as Lutetium-177 and Actinium-225). In recent years, the research activity of her group has focused on the development of radiolabeled nanoparticles for theranostic (diagnostic and therapeutic) applications.

Dr. Bouziotis has 65 publications in peer-reviewed journals, 1 book and 1 book chapter, more than 200 participations in international and national conferences, and many participations in national and international programs.

Selected Publications

Selected Grants

COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals

2020-2024 | European Cooperation in Science and Technology (COST)

The purpose of the COST Action CA19114 entitled "Network for Optimized Astatine-labeled Radiopharmaceuticals" (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: 211At) and its application in Targeted A...


COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"

2018-2022 | European Cooperation in Science and Technology (COST)

The COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside" focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is ...


Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer

2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση

The present research project is focused on the development of iron oxide nanoparticles (IONPs) radiolabeled with 68Ga, for dual-modality molecular imaging of prostate cancer with PET/MRI. These NPs are functionalized with adequate pharmacophores (peptides or peptidomimetic molecules) so a...

INRASTES - Official Web Site
Skip to content